Preventive effect of rabeprazole and sucralfate on gastroduodenal mucosal injury in patients taking low-dose aspirin

Preventive effect of rabeprazole and sucralfate on gastroduodenal mucosal injury in patients taking low-dose aspirin - Preventive effect of rabeprazole and sucralfate on gastroduodenal mucosal injury in patients taking low-dose aspirin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001678

Enrollment

Registered

2009-02-02

Start date

2009-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients who have plan to receive low-dose aspirin

Interventions

rabeprazole: 10mg/day, 4 week given with aspirin 100mg/day scralfate 3g/day, 4 week given with aspirin 100mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have a plan to receive low-dose aspirin

Exclusion criteria

Exclusion criteria: 1.taking low-dose aspirin 2.below 20 years of age 3.contraindication against rabeprazole and sucralfate 4.malignancy 5.pregnancy

Design outcomes

Primary

Measure	Time frame
Change of endoscopic finding before and 4 weeks after initiating low-dose aspirin (Comparison between rabeprazole and sucralfate)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026